Market Intelligence, Clinical Progress, and High-Purity Reagents for Nav1.2 Epilepsy and Neurodevelopmental Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCN2A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | SCN2A Lentivirus Premade Particles or Promise-ORF plasmid, full-length ORF (6.5 kb) with CMV promoter, GFP/Puro markers, sequence verified, HEK293 expressed (native glycosylation). | View SCN2A Products |
| Electrophysiology Platform | SCN2A Stable Cell Line Construction Service, high membrane expression (>1nA peak current), endotoxin <1EU/µg, suitable for automated patch clamp. | View SCN2A Products |
| Mutant Library | SCN2A EIEE variants (R1882Q, R853Q) and other clinical GoF/LoF mutants, available as lentivirus or plasmid, sequence verified, for mechanism studies and precision screening. | View SCN2A Products |
| Benchmark Antibody | Anti-SCN2A recombinant control antibody, positive control for western blot and IHC. | View SCN2A Products |
| Validator | SCN2A siRNA set, sequence-verified, for knockdown verification and specificity checks. | View SCN2A Products |
| Functional Control | Wild-type SCN2A expression plasmid, mammalian expression backbone for transfection studies. | View SCN2A Products |
| Selectivity Panel | SCN1A (Nav1.1) Lentivirus, ortholog control for counter-screening. | View SCN1A Products |
| Related Target | SCN8A (Nav1.6) Lentivirus, most abundant CNS sodium channel, essential for subtype selectivity profiling. | View SCN8A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subtype Selectivity (Nav1.1 vs Nav1.2 vs Nav1.6) | Human SCN1A/SCN2A/SCN8A ortholog lentivirus panel with matched titers (>10^8 TU/ml), sequence verified. |
| State-Dependent Binding (Resting vs Inactivated states) | High-expression stable cell lines suitable for automated electrophysiology (HEK293 background, low passage). |
| Mutant Pharmacology (EIEE11 variants) | Pre-built GoF mutant cell lines (R1882Q, R853Q) with confirmed elevated persistent current phenotype. |
| Cell Surface Expression Validation | Full-length SCN2A with extracellular HA-tag, flow cytometry compatible, endotoxin controlled. |
| Complex Membrane Expression | Premade lentivirus optimized for HEK293/CHO stable cell line generation, preserves native conformation. |
| False Positive Reduction | Sequence-verified siRNA included for precise specificity checks; recombinant positive control antibodies included for expression validation. |
Live SCN2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SCN2A therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum sodium channel blockers to highly selective modulators and gene therapies. As precision medicine takes hold in pediatric epilepsy and autism spectrum disorders, the next wave of R&D is targeting genotype-specific variants, requiring robust cellular models for both Gain-of-Function (GoF) and Loss-of-Function (LoF) mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotide (ASO) | Stoke Therapeutics, Biogen, Ultragenyx | SCN2A Developmental and Epileptic Encephalopathy (EIEE11), Autism Spectrum Disorder | Cell-based functional rescue assays; need high-expression SCN2A cell lines and reliable knockdown tools (siRNA/antibodies). |
| Small Molecule (State-dependent) | Praxis Precision Medicines, Xenon Pharmaceuticals | Refractory Epilepsy, DEE | Patch-clamp electrophysiology; need stable Nav1.2 currents and mutant cell lines (e.g., R1882Q, R853Q). |
| Gene Therapy | Novartis, Various Academic/Biotech | Severe Neurodevelopmental Disorders | Expression validation assays; need accurate ORF constructs and full-length functional channels. |